Chai Discovery's $400M Series C triples its value to $3.8bn, a fresh sign that AI drug discovery has moved from promise to deployment at big pharma.
Press’ post set off a firestorm of controversy within the Haskell community, which is small but vocal, and likely felt the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results